[Candidate drugs for non-alcoholic steatohepatitis (NASH)].
Terai
Shuji
S
terais@yamaguchi-u.ac.jp
Matsumoto
Toshihiko
T
Sakaida
Isao
I
D052242:Adiponectin / Q000502:physiology; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D015195:Drug Design; D005230:Fatty Acids, Nonesterified / Q000502:physiology; D005234:Fatty Liver / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007333:Insulin Resistance; D020738:Leptin / Q000502:physiology; D024821:Metabolic Syndrome / Q000150:complications; D054419:Receptors, Adiponectin; D011956:Receptors, Cell Surface / Q000819:agonists; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000502:physiology
C475418:ADIPOR1 protein, human; D052242:Adiponectin; D047228:Angiotensin II Type 1 Receptor Blockers; D000975:Antioxidants; D005230:Fatty Acids, Nonesterified; D000960:Hypolipidemic Agents; D020738:Leptin; D054419:Receptors, Adiponectin; D011956:Receptors, Cell Surface; D014409:Tumor Necrosis Factor-alpha